Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed Nov 14, 2024 · 10-Q · 45 days after period end · 0001558370-24-015731
| Metric | Q3 2024 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Net Income | -$2.32M | -$2.33M | -$1.37M |
| EPS Diluted | -$146.06 | -$0.20 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end
